|Bid||64.38 x 900|
|Ask||64.39 x 700|
|Day's Range||64.23 - 64.79|
|52 Week Range||63.88 - 88.85|
|PE Ratio (TTM)||6.80|
|Dividend & Yield||2.08 (3.23%)|
|1y Target Est||N/A|
Inovio Pharmaceuticals' experimental HIV vaccine is off to a promising start.
Falling hepatitis C sales are dragging sales and profit lower. Here's what could happen next.
Valeant and Gilead Sciences' are arguably cheap stocks, but big questions remain that still make them risky to buy.